查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1945891

瘧疾診斷市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、最終用戶、地區及競爭格局分類，2021-2031年）

Malaria Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球瘧疾診斷市場預計將從 2025 年的 8.6 億美元成長到 2031 年的 12.1 億美元，複合年成長率為 5.86%。

此市場領域涵蓋用於識別瘧疾原蟲的試劑和醫療設備（特別是顯微鏡、快速診斷測試和分子檢測）的生產和供應。推動這一成長的關鍵因素包括國際社會對瘧疾消除舉措的持續財政支持，以及在瘧疾高負擔地區迫切需要準確的就地檢驗以輔助治療決策。全球基金在2024年發布的一份報告預測，“將有3.6億例疑似瘧疾病例接受檢測”，這一數字凸顯了全球衛生框架對診斷覆蓋率的持續關注。

市場概覽
預測期 2027-2031
市場規模：2025年 8.6億美元
市場規模：2031年 12.1億美元
複合年成長率：2026-2031年 5.86%
成長最快的細分市場 快速診斷測試
最大的市場 亞太地區

阻礙市場發展的主要障礙是寄生蟲中pfhrp2和pfhrp3基因缺失的發生率不斷上升，導致最常用的基於抗原的快速診斷測試失效。這種生物抗藥性迫使人們採用替代的、通常更昂貴的診斷設備，從而使供應鏈管理更加複雜，並在資源匱乏的環境中加劇國家衛生計畫預算的壓力。

市場促進因素

增加國際津貼和財政支持對全球瘧疾診斷市場至關重要，尤其考慮到瘧疾負擔沉重的國家對外部援助的依賴程度。全球基金和美國總統瘧疾控制舉措等機構為資源匱乏地區採購快速診斷檢測套組和顯微鏡試劑提供了必要的資金。這些資金保障了供應鏈，並激勵製造商在利潤微薄的情況下維持生產水準。根據Devex網站2024年3月發表的題為「國會宣布支出協議」的報導，美國政府在其2024會計年度預算中核准了7.95億美元的雙邊瘧疾控制項目專項預算。然而，人們仍然擔憂長期的資金永續性。健康政策觀察組織在2024年4月世界瘧疾日發布的報告指出，實現全球瘧疾控制目標的年度資金缺口已擴大至約37億美元。

地方性瘧疾流行區域疾病負擔日益加重，氣候變遷導致感染區域擴大，直接推動了對診斷檢測的需求。氣候模式的改變正迫使蚊子向傳統上無瘧疾的高海拔和高緯度地區遷徙，使原本不常出現瘧疾的人面臨感染風險，因此必須實施快速篩檢措施。這種地理和人口結構的變化迫使各國衛生系統擴大就地檢驗盒的儲備，以應對疑似病例的激增並避免疫情爆發。根據路透社2023年12月發表的題為《全球瘧疾病例上升》的報導，預計2022年全球瘧疾病例將達到2.49億例，主要原因是巴基斯坦和衣索比亞等國的疫情爆發。這迫使生產商將分銷網路擴展到這些新的感染熱點地區。

市場挑戰

pfhrp2 和 pfhrp3 基因缺失的出現對全球瘧疾診斷市場構成了嚴重的生物學障礙。這些基因突變會導致標準且經濟高效的快速診斷測試出現假陰性結果，從根本上削弱了初始檢測程序的可靠性。因此，醫療系統被迫轉向其他診斷技術，而這些技術通常高成本，物流也更複雜。這種對替代方案的迫切需求在市場上造成了巨大的摩擦，需要對供應鏈進行根本性的改革以支持非 HRP2 檢測，從而導致採購和分銷效率下降。

這項挑戰阻礙了市場成長，因為它將原本用於擴張的關鍵資金轉移。各國衛生舉措被迫將有限的預算重新分配給檢驗和採購更昂貴的替代設備，而不是將診斷服務擴展到服務不足的地區。這種衝擊的規模巨大且影響廣泛，世界衛生組織 (WHO) 2024 年的報告指出，「在 40 多個國家已發現 pfhrp2 和 pfhrp3 基因缺失」。這種廣泛的影響迫使市場進入高成本的產品配方調整期，導致高負擔地區的普及速度放緩。

市場趨勢

將人工智慧 (AI) 和機器學習技術整合到數位顯微鏡中，透過自動檢測和定量寄生蟲，正在改變診斷標準，有助於緩解瘧疾流行地區熟練顯微鏡操作人員嚴重短缺的問題。這些先進的光學系統採用深度學習演算法，能夠以一致的準確度檢查血液塗片，顯著降低高強度環境下人工閱片固有的人為誤差率。這項技術進步對於準確檢測非惡性瘧疾原蟲和低寄生蟲血症病例尤其重要，因為這些病例往往會被傳統的目視檢查漏診。正如2024年11月發表在《韓國生物醫學評論》上的報導「Noul 在美國會議上推出具有卓越準確度的人工智慧瘧疾診斷工具」所報道，在奈及利亞進行的臨床試驗表明，人工智慧驅動的 miLab MAL 平台靈敏度高達94.4%，顯著優於傳統的現場人工顯微鏡檢查。

為了克服基於抗原的快速檢測靈敏度不足以及集中式PCR檢查室的後勤障礙，醫療系統正迅速轉向照護現場診斷平台。透過將核酸擴增技術整合到攜帶式電池供電設備中，製造商使地區級衛生中心能夠以基因檢測的準確性確診疑似病例，這對於識別抗藥性標記和監測根除工作至關重要。分子檢測的這種去中心化透過建立基於儀器安裝和耗材銷售的新收入來源，增強了市場。根據2024年5月《BioSpectrum India》一篇報導「MolBio Diagnostics採用新時代技術，於2024年推出顛覆性產品」的文章，MolBio Diagnostics預計在2024-2025會計年度的收入將達到1200億印度盧比，這主要得益於其Truenat平台在其上的廣泛部署資源。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球瘧疾診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按技術分類（分子診斷測試、快速診斷測試、其他）
    • 依最終使用者（醫院/診所、診斷中心、居家醫療、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美瘧疾診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲瘧疾診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區瘧疾診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲瘧疾診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲瘧疾診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球瘧疾診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Access Bio., Inc.
  • Abbott Laboratories
  • Premier Medical Corporation Pvt. Ltd.
  • Sysmex Partec GmbH
  • bioMerieux
  • Beckman Coulter, Inc.
  • Siemens Healthineers
  • Leica Microsystems GmbH
  • Nikon Corporation
  • Olympus Corporation
  • Bio-Rad Laboratories, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15000

The Global Malaria Diagnostics Market is projected to expand from USD 0.86 Billion in 2025 to USD 1.21 Billion by 2031, registering a CAGR of 5.86%. This market sector covers the production and provision of reagents and medical devices-specifically microscopy, Rapid Diagnostic Tests, and molecular assays-designed to identify Plasmodium parasites. Key factors fueling this growth include continuous international financial support for malaria eradication initiatives and the urgent requirement for precise point-of-care testing to direct treatment in regions with high disease burdens. As noted by 'The Global Fund' in '2024', '360 million suspected cases of malaria were tested', a figure that emphasizes the ongoing focus on diagnostic reach within global health frameworks.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.86 Billion
Market Size 2031USD 1.21 Billion
CAGR 2026-20315.86%
Fastest Growing SegmentRapid Diagnostic Test
Largest MarketAsia Pacific

A major obstacle hindering market progression is the rising occurrence of pfhrp2 and pfhrp3 gene deletions in parasites, which causes the most commonly utilized antigen-based Rapid Diagnostic Tests to fail. This biological resistance compels the adoption of alternative, frequently costlier diagnostic instruments, thereby complicating supply chain management and straining budget allocations for national health programs in resource-constrained environments.

Market Driver

Rising international grants and funding act as the cornerstone for the Global Malaria Diagnostics Market, especially considering the dependence of high-burden countries on external assistance. Entities like The Global Fund and the U.S. President's Malaria Initiative supply the necessary capital to acquire rapid diagnostic tests and microscopy reagents globally for low-resource areas. This funding secures the supply chain and motivates manufacturers to uphold production levels despite thin profit margins. According to Devex in March 2024, the article 'Congress releases spending deal' noted that the U.S. government authorized US$ 795 million specifically for bilateral malaria programs in the 2024 fiscal budget; however, long-term financial viability is a concern, as a 'World Malaria Day' report by Health Policy Watch in April 2024 indicated the annual funding gap for global malaria targets has grown to roughly US$ 3.7 billion.

The increasing disease load in endemic areas, worsened by the climate-driven widening of transmission zones, is directly fueling the demand for diagnostic testing volumes. Changing weather patterns are causing mosquitoes to migrate to higher elevations and previously malaria-free latitudes, exposing unaccustomed populations to infection and demanding the swift implementation of screening measures. This geographical and demographic shift obliges national health systems to bolster their stocks of point-of-care solutions to handle the spike in suspected cases and avert outbreaks. As reported by Reuters in December 2023 in the 'Global malaria cases rise' article, global malaria cases were estimated at 249 million in 2022, largely due to outbreaks in nations such as Pakistan and Ethiopia, forcing manufacturers to expand distribution networks to these emerging hotspots.

Market Challenge

The growing incidence of pfhrp2 and pfhrp3 gene deletions constitutes a severe biological hurdle for the Global Malaria Diagnostics Market. These genetic mutations lead standard, cost-efficient rapid diagnostic tests to yield false-negative outcomes, fundamentally compromising the reliability of initial testing procedures. Consequently, healthcare systems must shift toward alternative diagnostic techniques that are generally more costly and logistically intricate. This urgent requirement for substitution generates considerable market friction, as supply chains require overhaul to support non-HRP2 tests, resulting in setbacks regarding procurement and distribution efficiency.

This difficulty inhibits market growth by redirecting crucial financial assets away from expansion efforts. National health initiatives are forced to reassign restricted budgets toward validating and acquiring these more expensive alternative instruments instead of broadening diagnostic access for underserved communities. The scale of this disruption is significant and widespread; according to the 'World Health Organization' in '2024', 'pfhrp2 and pfhrp3 gene deletions were reported in over 40 countries'. This broad reach compels the market into an expensive period of product restructuring, thereby retarding the pace of volume adoption in high-burden areas.

Market Trends

The incorporation of Artificial Intelligence and Machine Learning into Digital Microscopy is transforming diagnostic standards by automating parasite detection and quantification, helping to resolve the acute scarcity of trained microscopists in endemic zones. These sophisticated optical systems employ deep learning algorithms to examine blood smears with uniform accuracy, drastically lowering human error rates common in manual slide reading within high-volume environments. This technological advancement is especially critical for correctly detecting non-falciparum species and low-parasitemia cases often overlooked by standard visual checks. As reported by Korea Biomedical Review in November 2024, in the article 'Noul showcases AI-powered malaria diagnostic tool with superior accuracy at US meet', a clinical trial in Nigeria showed that the AI-enabled miLab MAL platform reached a sensitivity of 94.4 percent, significantly surpassing traditional manual microscopy in the field.

The shift toward Point-of-Care Molecular Diagnostic Platforms is rapidly gathering momentum as health systems aim to overcome the sensitivity constraints of antigen-based rapid tests and the logistical hurdles of central laboratory PCR. By compacting nucleic acid amplification technology into portable, battery-powered units, manufacturers allow district-level centers to verify suspected cases with genomic precision, which is vital for identifying drug-resistance markers and overseeing elimination efforts. This decentralization of molecular testing reinforces the market by establishing new revenue streams based on instrument placement and consumable cartridge sales. According to BioSpectrum India in May 2024, in the 'MolBio Diagnostics deploys new-age technologies to launch innovative products in 2024' article, Molbio Diagnostics anticipated revenue of Rs 1200 crore for the 2024-25 fiscal year, primarily fueled by the broader rollout of its Truenat molecular platform in resource-constrained markets.

Key Market Players

  • Access Bio., Inc.
  • Abbott Laboratories
  • Premier Medical Corporation Pvt. Ltd.
  • Sysmex Partec GmbH
  • bioMerieux
  • Beckman Coulter, Inc.
  • Siemens Healthineers
  • Leica Microsystems GmbH
  • Nikon Corporation
  • Olympus Corporation
  • Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Malaria Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Malaria Diagnostics Market, By Technology

  • Molecular Diagnostic Tests
  • Rapid Diagnostic Test
  • Others

Malaria Diagnostics Market, By End User

  • Hospitals & Clinics
  • Diagnostic Centers
  • Home care
  • Others

Malaria Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Malaria Diagnostics Market.

Available Customizations:

Global Malaria Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Malaria Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (Molecular Diagnostic Tests, Rapid Diagnostic Test, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Diagnostic Centers, Home care, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Malaria Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Malaria Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Malaria Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Malaria Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By End User

7. Europe Malaria Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Malaria Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By End User
    • 7.3.2. France Malaria Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Malaria Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Malaria Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Malaria Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By End User

8. Asia Pacific Malaria Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Malaria Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By End User
    • 8.3.2. India Malaria Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Malaria Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Malaria Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Malaria Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By End User

9. Middle East & Africa Malaria Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Malaria Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Malaria Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Malaria Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By End User

10. South America Malaria Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Malaria Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Malaria Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Malaria Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Malaria Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Access Bio., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories
  • 15.3. Premier Medical Corporation Pvt. Ltd.
  • 15.4. Sysmex Partec GmbH
  • 15.5. bioMerieux
  • 15.6. Beckman Coulter, Inc.
  • 15.7. Siemens Healthineers
  • 15.8. Leica Microsystems GmbH
  • 15.9. Nikon Corporation
  • 15.10. Olympus Corporation
  • 15.11. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer